Range
- - -
Vol / Avg.
-/0.3K
Div / Yield
-
52 Wk
4.43 - 8.5
Mkt Cap
759.9M
Payout Ratio
-
Open
-
P/E
-
EPS
0
Shares
89.4M
Outstanding
-
Total Float
-
There is no Press for this Ticker
Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial, and its income consists of license fees, milestone and option payments, grant income, and fees from research and development collaborations. Its geographical segments are the United Kingdom and Germany.

Related Companies

TickerCompanyChg %Mkt Cap
SLNCFSilence Therapeutics0%759.9M

Silence Therapeutics Company Questions & Answers

Q

How do I buy Silence Therapeutics (SLNCF) stock?

A

You can purchase shares of Silence Therapeutics (OTC: SLNCF) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Silence Therapeutics's (SLNCF) main competitors?

A

There are no as such competitors for Silence Therapeutics.

Q

What is the target price for Silence Therapeutics?

A

There is no analysis for Silence Therapeutics

Q

How much is Silence Therapeutics (SLNCF) stock ?

A

The stock price for Silence Therapeutics (OTC: SLNCF) is $8.5 last updated Fri May 07 2021 16:06:11 GMT+0000 (Coordinated Universal Time).

Q

When is the next Silence Therapeutics (SLNCF) dividend?

A

There are no upcoming dividends for Silence Therapeutics.

Q

When is Silence Therapeutics (OTC:SLNCF) reporting earnings?

A

There are no earnings for Silence Therapeutics

Q

When is the upcoming split for SLNCF?

A

There is no upcoming split for Silence Therapeutics.